C3 Protein (Complement Component 3)

Overview

C3 Protein (Complement Component 3) is a central hub of the complement system and plays a critical role in innate immunity and neuroinflammation. It is one of the most abundant proteins in the complement system and serves as a convergence point for all three complement activation pathways. In the central nervous system, C3 is produced by neurons, astrocytes, microglia, and oligodendrocytes, making it a key mediator of neuroinflammatory processes in neurodegenerative diseases.

Introduction

Complement Component 3 (C3) is the central molecule of the complement system, a key component of innate immunity. The complement system consists of over 50 proteins that work together to opsonize pathogens, recruit immune cells, and lyse foreign cells. C3 is the most abundant complement protein in plasma and serves as the convergence point for all three complement activation pathways: the classical pathway, the lectin pathway, and the alternative pathway [1].

In the brain, C3 plays a dual role. Under normal conditions, it contributes to synaptic pruning during development, a process by which excess synapses are eliminated to refine neural circuits [2]. However, dysregulated complement activation is implicated in the pathogenesis of multiple neurodegenerative diseases, where excessive complement activation contributes to neuroinflammation, synaptic loss, and progressive neuronal damage [3].

---

Structure

C3 is a large glycoprotein composed of an alpha chain (~110 kDa) and a beta chain (~70 kDa) linked by disulfide bonds:

Domain Architecture

• CUB domain: Required for proper folding and stability

• Thioester-containing domain (TED): Contains a reactive thioester bond that allows C3b to covalently attach to pathogen surfaces

• Linker domain: Connects TED to the alpha chain

• C345c domain: Found in C3, C4, and C5, involved in protein-protein interactions

• Anaphylatoxin domain (C3a): Released upon activation as a potent inflammatory mediator

Key Structural Features

Feature	Description
Thioester bond	Reactive cysteine-methionine ester that covalently bonds to hydroxyl or amine groups on pathogen surfaces
Protease cleavage sites	Multiple sites for factor I-mediated cleavage and downstream complement activation
Conformational changes	Dramatic structural rearrangements upon activation expose functional domains

Alternative Splicing Variants

• C3a: Anaphylatoxin fragment (9 kDa)

• C3b: Opsonin fragment (large fragment after cleavage)

• C3c: Large fragment remaining after further cleavage

• C3d: Fragment involved in immune complex clearance

• C3dg: Cell-bound fragment

---

Normal Function

Complement Activation Pathways

C3 serves as the central hub for all three complement activation pathways:

Classical Pathway

Initiated by antigen-antibody complexes (C1q binding to IgG/IgM), leading to C1r/C1s activation, which then cleaves C4 and C2 to form the C3 convertase (C4b2a).

Lectin Pathway

Activated by mannose-binding lectin (MBL) or ficolins binding to carbohydrate patterns on pathogens, also leading to C4b2a formation.

Alternative Pathway

Spontaneous C3 tick-over produces C3(H2O), which then binds Factor B. Factor D cleaves Factor B to form the C3 convertase (C3bBb), which can amplify complement activation on surfaces that lack complement regulators.

Key Biological Functions

Function	Description	Mechanism
Opsonization	Marks pathogens for phagocytosis	C3b covalently attaches to pathogen surfaces
Inflammation	Recruits immune cells	C3a anaphylatoxin releases histamine from mast cells
Cell lysis	Direct pathogen killing	C5b-9 membrane attack complex formation
Immune clearance	Removes immune complexes	C3b/d receptors on erythrocytes and macrophages
Synaptic pruning	Developmental refinement	Complement-mediated synapse elimination

CNS-Specific Functions

In the central nervous system, complement proteins serve specialized functions:

1. Developmental synaptic pruning: During early development, complement components C1q and C3 tag synapses for elimination by microglia [4]

2. Axonal guidance: Complement proteins participate in neural circuit formation

3. Neuroprotection: Low-level complement activation can be neuroprotective

4. Astrocyte-neuron communication: C3 expressed by astrocytes modulates neuronal function

---

Role in Neurodegenerative Diseases

Alzheimer’s Disease

C3 plays a significant role in Alzheimer’s disease pathogenesis through multiple mechanisms:

Amyloid-Beta Pathology

• C3 co-localizes with amyloid-beta plaques in AD brain [5]

• Complement activation accelerates Aβ aggregation and deposition

• C3b opsonization of Aβ enhances microglial phagocytosis but can also trigger chronic inflammation

• The balance between complement activation and inhibition affects Aβ clearance efficiency

Neurofibrillary Tangles

• Complement proteins bind to hyperphosphorylated tau tangles [6]

• Complement activation may exacerbate tau pathology propagation

• Neuronal C3 expression is upregulated in tauopathies

Synaptic Loss

• C1q and C3 mediate complement-dependent synaptic elimination in AD [7]

• Early synaptic loss correlates with complement activation

• Microglial complement receptor 3 (CR3) mediates synaptic phagocytosis

Neuroinflammation

• Chronically elevated C3a and C5a anaphylatoxins promote neuroinflammation

• C3a receptor (C3aR) signaling on microglia enhances pro-inflammatory cytokine production

• The neurovascular unit shows complement dysregulation in AD

Parkinson’s Disease

In Parkinson’s disease, C3 contributes to dopaminergic neuron degeneration:

• C3 is present in Lewy bodies [8]

• Microglial C3 activation in the substantia nigra [9]

• Complement-mediated inflammation accelerates alpha-synuclein pathology

• C3a receptor antagonism shows promise in PD models

Amyotrophic Lateral Sclerosis (ALS)

C3 plays a role in motor neuron degeneration:

• Activated microglia produce C3 in ALS spinal cord [10]

• C3 expression is elevated in sporadic and familial ALS

• Complement activation contributes to motor neuron death

• Astrocyte C3 production increases in ALS models

Multiple Sclerosis

Complement is central to demyelination in MS:

• Complement-mediated oligodendrocyte death

• Myelin opsonization and phagocytosis

• Clinical trials of complement inhibitors in MS

• C5a receptor antagonists in development

Other Neurodegenerative Diseases

• Huntington’s Disease: C3 upregulation in striatal neurons

• Frontotemporal Dementia: Complement activation in tau pathology

• Creutzfeldt-Jakob Disease: Prion-mediated complement activation

---

Molecular Mechanisms

Complement Activation in the Brain

The complement cascade in the brain differs from systemic complement:

1. Local synthesis: Brain cells produce complement proteins locally

2. Blood-brain barrier regulation: Limited peripheral complement penetration

3. Cell-type specific expression: Different cell types express different complement components

4. Unique regulation: Brain complement is regulated differently than plasma complement

Signaling Pathways

C3a and C3b trigger distinct signaling cascades:

• C3aR signaling: G-protein coupled receptor signaling, cAMP modulation, MAPK activation

• CR3 (CD11b/CD18): Tyrosine kinase signaling, phagocytosis

• CR1 (CD35): Inhibition of complement activation, immune complex clearance

Neuroinflammatory Cross-talk

Complement interacts with other neuroinflammatory pathways:

• Toll-like receptor (TLR) signaling: Synergistic inflammation

• NLRP3 inflammasome: Complement-induced inflammasome activation

• NF-κB pathway: Complement-mediated NF-κB activation

• Cytokine networks: Interleukin-1β, TNF-α, and complement form inflammatory loops

---

Therapeutic Targeting

Complement inhibitors represent a promising therapeutic approach for neurodegenerative diseases:

Clinical-Stage Approaches

Drug/Agent	Target	Status	Company/Indication
Eculizumab	C5	Approved (PNH, aHUS)	Alexion - Exploring CNS indications
Ravulizumab	C5	Approved (PNH, aHUS)	Alexion - Long-acting eculizumab
Pegcetacoplan	C3	Approved (PNH)	Apellis - Geographic atrophy
AMY-101	C3	Phase 2	Amyndas - Periodontitis, MS
Avacopan	C5aR	Approved (ANCA vasculitis)	ChemoCentryx - Exploring CNS

Preclinical and Research Agents

Agent	Mechanism	Research Stage
C3aR antagonists	Block C3a signaling	PD models
C3 Convertase inhibitors	Prevent C3b generation	Animal models
CR3 agonists	Enhance phagocytosis	Preclinical
C1q inhibitors	Prevent upstream activation	AD models

Gene Therapy Approaches

• AAV-delivered complement regulatory proteins

• CRISPR-based approaches to modulate complement gene expression

• Cell-type specific targeting using engineered vectors

Challenges in CNS Delivery

• Blood-brain barrier limits complement inhibitor access

• Local brain delivery required (intrathecal, intraventricular)

• Balancing beneficial vs. harmful complement functions

• Timing of intervention in disease progression

---

Animal Models

Key experimental models for studying C3 in neurodegeneration:

• C3 knockout mice: Protective in some neurodegeneration models

• C3 transgenic mice: Show enhanced pathology

• Human C3 knock-in mice: Express human C3 for therapeutic testing

• AD models (APP/PS1): Complement deficiency reduces pathology

• PD models (α-syn): C3aR antagonists show neuroprotection

---

Biomarker Potential

C3 and its cleavage products serve as potential biomarkers:

• C3a: Elevated in AD and PD cerebrospinal fluid

• C3b/iC3b: Marker of complement activation

• C3d: Immune complex and complement activation marker

• Soluble C5b-9: Terminal complement complex

---

Genetic Associations

• C3 gene polymorphisms linked to AD risk

• Complement regulatory protein variants modify disease progression

• Expression quantitative trait loci (eQTLs) in brain tissue

---

See Also

• Complement System Pathway

• Neuroinflammation Mechanisms

• Microglia in Neuroinflammation

• Alzheimer’s Disease

• Parkinson’s Disease

• Amyotrophic Lateral Sclerosis

• Multiple Sclerosis

• Synaptic Pruning

• C1q Protein

• C5a Protein

• Astrocyte-Neuron Communication

---

External Links

• UniProt C3: P01024 - Protein sequence and structure database

• NCBI Gene: C3 - Gene information

• OMIM: C3 - Genetic disorders

• Complement Database - Complement system resources

---